Valneva to launch trial for booster use of its COVID-19 vaccine candidate

PARIS, May 4 (Reuters) – French drugmaker Valneva (VLS.PA) said on Wednesday it will conduct a trial about the use of its COVID-19 vaccine candidate VLA2001 as a booster jab following a mRNA vaccination or natural infection.

The trial will be conducted in the Netherlands and results are expected in the third quarter of 2022, the statement said.

Valneva logo and stock graph are seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

The VLA2001-307 trial will be the company’s first clinical trial to provide booster data following primary vaccination with an mRNA vaccine or natural COVID-19 infection.

Reporting by Dominique Vidalon , Editing by Tassilo Hummel

Our Standards: The Thomson Reuters Trust Principles.


Reuters source: